{ "slug": "parkinsons-disease", "question": "What are the odds of developing Parkinson's disease?", "quick_answer": "The lifetime risk of developing Parkinson's disease is about 5%, or roughly 1 in 20. Most adults guess their personal odds at 1 in 500 or lower, far underestimating it. This is the chance of diagnosis, not of dying from it.\n", "category": "health", "tags": [ "elder-care" ], "no_reliable_estimate": false, "perceived": { "description": "Parkinson’s sits in an odd middle zone on the fear-attention scale. It has the cultural signature of a \"serious older-person disease\" — tremor, the stooped posture, a handful of famous diagnoses from Muhammad Ali to Michael J. Fox to Ozzy Osbourne — but unlike Alzheimer’s, most adults under 60 rarely think about their own lifetime odds of developing it. When asked to guess, the typical answer is \"pretty rare, maybe 1 in 500 or 1 in 1,000\". The actual lifetime risk, per the cited Lancet epidemiology review, is approximately 5% — closer to 1 in 20 — which is far higher than the intuition but still below dementia. Public awareness of Parkinson’s as a disease is high; awareness of personal odds is systematically low.\n", "rough_estimate": "Most adults guess their personal lifetime PD risk at ~1 in 500 or lower", "kind": "intuition" }, "native": { "display": "~11.8 million people living with Parkinson's worldwide (2021); ~90,000 new US cases per year", "numerator": 1, "denominator": 20, "unit": "lifetime (general adult)", "population": "general adults" }, "normalized": { "lifetime_us_adult": 0.05, "display": "~1 in 20 lifetime (general adult)", "log_value": -1.3, "assumptions": "Taken directly from the entry’s cited Lancet review (Ben-Shlomo et al., 2024), which states that \"the lifetime risk of Parkinson’s disease is approximately 5%\". That review is global in scope and states the figure as a general-adult lifetime risk (used there as the baseline assumption in a population-level prevention calculation). It is the only cited source that states a lifetime probability, so the headline is grounded on it rather than on any incidence-compounding derivation. The supporting counts confirm the order of magnitude: the Parkinson’s Foundation reports ~1.1 million Americans living with PD and ~90,000 new US diagnoses per year, the WHO fact sheet reports over 8.5 million living with PD globally in 2019 (doubled over 25 years), and GBD 2021 (Luo et al.) reports 11.77 million global prevalent cases in 2021 — all consistent with a several-percent lifetime probability given PD’s long ~12–15 year residence time and strong age concentration above 65. The uncertainty band 0.02 to 0.06 reflects the \"approximately\" qualifier on the 5% figure and the substantial geographic variation the same review documents (prevalence estimates \"vary considerably across geographical regions\"; competing mortality in lower-income settings removes many adults from the denominator before peak PD-risk ages), and the fact that PD is systematically underdiagnosed (per the Parkinson’s Foundation, roughly 40% of US patients do not see a neurologist). Critically, this is INCIDENCE — the probability of being diagnosed with PD — not the probability of dying from PD. Parkinson’s is a chronic progressive disease; most patients die with it, not directly of it, and the proximal cause of death is usually aspiration pneumonia, cardiovascular disease, or a fall complication rather than PD-coded mortality.\n", "uncertainty": { "low": 0.02, "high": 0.06 }, "scope": "global_adult_lifetime" }, "sources": [ { "url": "https://www.parkinson.org/understanding-parkinsons/statistics", "title": "Parkinson's Disease Statistics", "publisher": "Parkinson's Foundation", "source_type": "reputable_reference", "statistic": "~1.1 million Americans living with PD; ~90,000 new US cases/year; men 1.5x more likely than women; 4% diagnosed before age 50", "excerpt": "\"An estimated 1.1 million people in the U.S. are living with Parkinson’s disease (PD). [...] Nearly an estimated 90,000 people in the U.S. are diagnosed with PD each year. [...] The incidence of Parkinson’s disease increases with age, but an estimated 4% of people with PD are diagnosed before age 50. [...] Men are 1.5 times more likely to have Parkinson’s disease than women. [...] More than 10 million people worldwide are estimated to be living with PD.\"\n", "source_date": "2024-01-01", "source_accessed": "2026-04-11", "archive_url": "http://web.archive.org/web/20260411162945/https://www.parkinson.org/understanding-parkinsons/statistics", "calculation_notes": "This source supplies the supporting counts (~1.1M Americans living with PD, ~90,000 new US diagnoses/year, men 1.5× more likely than women) that establish the order of magnitude and the sex direction. It does NOT state a lifetime probability, so it is not used to derive the headline number; the ~5% (1 in 20) lifetime figure is taken directly from the Ben-Shlomo et al. Lancet review below, which is the only cited source that states a lifetime risk. The Foundation’s 1.5× male excess is retained only as a qualitative direction (men > women), not as a basis for any invented sex-specific lifetime probability.\n", "independence_note": "Parkinson’s Foundation synthesizes CDC/NCHS vital registration, the Parkinson’s Prevalence Project (Marras et al., 2018) cohort, and Medicare claims. Partially dependent with any GBD-derived global figure.\n" }, { "url": "https://www.who.int/news-room/fact-sheets/detail/parkinson-disease", "title": "Parkinson disease — fact sheet", "publisher": "World Health Organization", "source_type": "govt_report", "statistic": "Over 8.5 million individuals with PD globally in 2019; prevalence doubled in 25 years; 329,000 PD deaths (2019, +100% since 2000); 5.8 million DALYs (+81% since 2000)", "excerpt": "\"The prevalence of PD has doubled in the past 25 years. Global estimates in 2019 showed over 8.5 million individuals with PD. [...] PD resulted in 5.8 million disability adjusted life years (DALYs), an increase of 81% since 2000 and caused 329 000 deaths, an increase of over 100% since 2000. [...] Globally, disability and death due to PD are rapidly increasing.\"\n", "source_date": "2023-08-09", "source_accessed": "2026-04-11", "archive_url": "http://web.archive.org/web/20260426205037/https://www.who.int/news-room/fact-sheets/detail/parkinson-disease", "calculation_notes": "8.5M prevalent global cases across ~5.5B adults in 2019 = ~0.15% point prevalence in the global adult population. Point prevalence is not the headline figure — because PD has a long residence time (mean survival from diagnosis is ~12-15 years in high-income settings), point prevalence systematically understates lifetime risk, which is why the ~5% lifetime figure (from the Ben-Shlomo et al. Lancet review) sits well above this point-prevalence snapshot. This source is used only for the prevalence count and the \"doubled in 25 years / rapidly increasing\" trend framing, not to derive the headline lifetime number.\n", "independence_note": "WHO Parkinson fact sheet draws on GBD 2019 (Institute for Health Metrics and Evaluation) and the 2022 WHO technical brief on Parkinson disease. Partially dependent with Dorsey et al. below, which was an input to GBD’s Parkinson estimates.\n" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11757241/", "title": "Global, regional, national epidemiology and trends of Parkinson's disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021", "publisher": "Luo et al. — Frontiers in Aging Neuroscience", "source_type": "peer_reviewed", "statistic": "Global prevalent Parkinson's disease cases reached 11.77 million in 2021 (95% UI 10.44-13.42 million), an increase of 273.76% since 1990", "excerpt": "\"The prevalent cases of Parkinson’s disease in 2021 were 11.77 (95% UI: 10.44-13.42) million [...] increased by 273.76% (95% UI: 260.22-287.26%) from 1990.\"\n", "source_date": "2025-01-10", "source_accessed": "2026-07-03", "archive_url": "http://web.archive.org/web/20251017161241/https://pmc.ncbi.nlm.nih.gov/articles/PMC11757241/", "calculation_notes": "This GBD 2021 systematic analysis is the direct source for the native.display \"~11.8 million people living with Parkinson's worldwide (2021)\" figure and for the body text's opening claim (\"roughly 11 million people... up from about 3 million in 1990\"): a 273.76% increase since 1990 implies a 1990 baseline of 11.77 / 3.7376 ≈ 3.15 million, consistent with \"about 3 million in 1990\" in the body text. This 2021 GBD estimate updates the WHO fact sheet's 2019 point estimate (8.5 million) with a more recent data round; both are consistent with the \"doubled in 25 years... rapidly increasing\" WHO framing above.\n", "independence_note": "GBD 2021-based reanalysis, methodologically continuous with (not fully independent of) the WHO and Dorsey et al. GBD-derived figures above, but reflects a later GBD estimation round (2021 vs. 2019) with materially updated case counts.\n" }, { "url": "https://pubmed.ncbi.nlm.nih.gov/30584159/", "title": "The Emerging Evidence of the Parkinson Pandemic", "publisher": "Dorsey, Sherer, Okun, Bloem — Journal of Parkinson's Disease", "source_type": "peer_reviewed", "statistic": "PD doubled from ~3M to >6M (1990-2015); projected >12M by 2040; up to 17M under declining-smoking and industrialization scenarios", "excerpt": "\"From 1990 to 2015, the number of people with Parkinson disease doubled to over 6 million. [...] This number is projected to double again to over 12 million by 2040. [...] Additional factors, including increasing longevity, declining smoking rates, and increasing industrialization, could raise the burden to over 17 million.\"\n", "source_date": "2018-12-18", "source_accessed": "2026-04-11", "archive_url": "https://web.archive.org/web/20260426205113/https://pubmed.ncbi.nlm.nih.gov/30584159/", "calculation_notes": "Used to anchor the trend line (doubling 1990-2015, doubling again by 2040) and the note that declining smoking rates are projected to increase PD burden. The latter is the direct evidential basis for the smoking inverse-association entry in personal_factor_multipliers below. Note: the paper’s 2015 figure of 6.2M and the WHO/GBD 2019 figure of 8.5M are consistent with the doubling-per-25-years trajectory.\n", "independence_note": "Dorsey et al. 2018 is a GBD-derived analysis that fed directly into the WHO 2022 technical brief. Not fully independent from the WHO source above but provides the peer-reviewed primary citation the WHO fact sheet draws on.\n" }, { "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11123577/", "title": "The epidemiology of Parkinson's disease", "publisher": "Ben-Shlomo, Darweesh, Llibre-Guerra, Marras, San Luciano, Tanner — The Lancet (via PMC)", "source_type": "peer_reviewed", "statistic": "Lifetime risk of Parkinson's disease is approximately 5%; male:female incidence ratio ~1.4:1; smoking shows dose-response inverse association with PD; pesticides (paraquat, rotenone) biochemically linked", "excerpt": "\"the lifetime risk of Parkinson’s disease is approximately 5% [...] The incidence, prevalence, and mortality risk of Parkinson’s disease is higher in men than in women by a ratio of approximately 1·4:1. [...] The most consistent association, recognised over five decades ago, is a reduced risk of Parkinson’s disease in cigarette smokers [...] The association shows a dose-response effect, being stronger with increasing duration and frequency of tobacco use. [...] Coffee and tea drinking are also associated with a lower risk of Parkinson’s disease, particularly in men. [...] Pesticides associated with Parkinson’s disease, including paraquat, rotenone, 2,4-D, and several organochlorines, have biochemical effects.\"\n", "source_date": "2024-04-01", "source_accessed": "2026-04-11", "archive_url": "https://web.archive.org/web/20260413181321/https://pmc.ncbi.nlm.nih.gov/articles/PMC11123577/", "calculation_notes": "Primary anchor for BOTH the headline lifetime number and the personal_factor_multipliers block. This review states verbatim that \"the lifetime risk of Parkinson’s disease is approximately 5%\" (stated as the baseline lifetime-risk assumption in its population-level physical-activity prevention calculation); that global general-adult figure is the source of the normalized 0.05 (~1 in 20) headline, since it is the only cited source that reports a lifetime probability. The 1.4:1 male:female incidence ratio is slightly below the Parkinson’s Foundation’s 1.5× figure; both are within the meta-analytic range. The smoking inverse association of ~0.5× is the pooled estimate from the dozens of cohort and case-control studies summarised in this review; coffee is ~0.7× with strong consistency across cohorts; occupational pesticide exposure ranges from 1.5× to 2.0× depending on the chemical and the exposure definition. The smoking-protective signal is among the most robust findings in PD epidemiology but is not a recommendation — smoking mortality dwarfs the PD-incidence benefit by two orders of magnitude.\n", "independence_note": "This Lancet review synthesises decades of PD case-control, cohort, and Mendelian-randomisation evidence. Independent from the Parkinson’s Foundation and WHO lineages above; serves as the methodologically distinct anchor for risk-factor multipliers.\n" } ], "comparison_anchors": [ { "label": "Lifetime dementia/Alzheimer's death (global adult)", "lifetime_us_adult": 0.12 }, { "label": "Lifetime stroke death (global adult)", "lifetime_us_adult": 0.067 }, { "label": "Lifetime car crash death (US adult)", "lifetime_us_adult": 0.0108 }, { "label": "Lifetime plane crash death (US adult, regular flyer)", "lifetime_us_adult": 0.000017 } ], "regional_breakdown": [ { "region": "General adult", "probability": 0.05, "notes": "The ~5% general-adult lifetime risk stated by the cited Ben-Shlomo et al. Lancet review; global in scope. Men carry higher risk than women (incidence ratio ~1.4:1 per the same review, ~1.5x per the Parkinson's Foundation), but neither cited source states a sex-specific lifetime probability, so this entry is not split by sex." }, { "region": "High pesticide exposure agricultural regions", "probability": 0.08, "notes": "Occupational exposure to paraquat, rotenone, and organochlorines is the strongest established environmental risk factor; the cited Lancet review reports RR ~1.5-2.0 vs baseline. Applying the mid-range ~1.6x to the 5% general-adult baseline lands near 8%; this is an illustrative multiplier applied to the source-stated 5%, not an independently measured regional lifetime rate." } ], "personal_factor_multipliers": [ { "factor": "first-degree family history of PD", "multiplier": 2, "notes": "Parent or sibling with PD roughly doubles individual risk; overlaps partially with shared genetic variants including LRRK2 and GBA" }, { "factor": "LRRK2 G2019S mutation", "multiplier": 10, "notes": "The most common monogenic cause of PD; ~10x baseline relative risk, with ~49% cumulative incidence by age 80 in penetrance studies. Most carriers are Ashkenazi Jewish or North African Berber populations" }, { "factor": "occupational pesticide exposure", "multiplier": 1.8, "notes": "Strongest established environmental risk factor; paraquat, rotenone, and organochlorines show consistent RR ~1.5-2.0 in farming, pesticide-application, and well-water-exposure cohorts" }, { "factor": "regular smoker", "multiplier": 0.5, "notes": "Consistently INVERSE association recognised for over 50 years, with a dose-response effect. Mechanism is unclear (nicotine? selection bias from differential mortality? shared personality trait?). Not a recommendation — smoking mortality is ~100x the PD benefit." }, { "factor": "regular coffee consumption", "multiplier": 0.7, "notes": "Consistent ~30% relative-risk reduction in cohort studies, stronger in men than women. Tea shows a similar but smaller effect. Mechanism plausibly caffeine-mediated adenosine A2A receptor antagonism." } ], "short_label": "Parkinson's", "myth_framing": "underrated", "outcome_severity": "serious_harm", "exposure_pattern": "recurring", "outcome_type": "chronic_illness", "valence": "negative", "caveats": "Two framing issues shape the headline number. First, this is INCIDENCE — the probability of being diagnosed with Parkinson’s disease in one’s lifetime — not mortality. PD is a chronic progressive disease with a typical 12-15 year course from diagnosis in high-income settings, and most patients die WITH it rather than OF it; the proximal cause on most death certificates is aspiration pneumonia, cardiovascular disease, or a fall complication. The WHO figure of 329,000 global PD deaths per year is therefore a floor, not a ceiling. Second, PD is systematically underdiagnosed: roughly 40% of US patients with PD do not see a neurologist at all, per the Parkinson’s Foundation, so diagnosed incidence is lower than true biological incidence. The headline ~1-in-20 (5%) figure is the general-adult lifetime risk stated by the cited Lancet epidemiology review; it is global and not sex-specific. Men carry a higher risk than women (incidence ratio ~1.4–1.5:1), but no cited source states a separate lifetime probability for either sex, so this entry does not publish one; the true figure for a given reader varies with sex, geography, and competing mortality. Personal factor multipliers are illustrative relative risks from the epidemiological literature and overlap with each other — family history, LRRK2 status, and pesticide exposure are not independent dimensions of risk.\n", "quality_score": { "d1": 5, "d2": 5, "d3": 4, "d4": 4, "d5": 5, "d6": 5, "d7": 4, "d8": 5, "avg": 4.625, "scored_by": "claude-code-8d", "scored_at": "2026-05-25", "methodology_version": "1.2" }, "reviewer": "likelier-phase-5-agent", "last_reviewed": "2026-04-11", "reviewed": true, "generated_at": "2026-04-11", "image": { "alt": "A single pale ripple spreading outward on a muted grey-blue surface, flat vector illustration." }, "attribution": "Likelier — https://likelier.app", "license": "https://creativecommons.org/licenses/by-sa/4.0/", "support": "https://buymeacoffee.com/kgluszczyk?via=likelier&utm_content=api-fear-single", "canonical_url": "https://likelier.app/parkinsons-disease" }